FDA Preventative Changes: DDAVP, Norvir, Cipro CME/CE

News Maker: Yael Waknine CME Generator: Yael Waknine Disclosures Vent Date: Onward motion 1, 2006 ; Valid for accomplishment through Advance 1, 2007
Marching music 1, 2006 — The US Food and Drug Association activity (FDA) has approved tadalafil soft tablets 20mg labeling revisions to advise that desmopressin salt medical aid, os atomizer, rhinal tube, and tablets are contraindicated in patients with moderate to severe renal impairment; voriconazole and alfuzosin are contraindicated and phosphodiesterase type 5 inhibitors should be used with carefulness in patients receiving ritonavir therapy; and ciprofloxacin intravenous instillment is contraindicated in patients receiving tizanidine because of the risk for adverse events caused by elevated tizanidine levels.Desmopressin Ethanoate (DDAVP) Contraindicated in Patients With CrCl Less Than 50-mL/minute
On November 10, 2005, the FDA approved country labeling revisions for desmopressin salt insertion, os nasale water vapour, rhinal tube, and tablets ( DDAVP , made by Aventis Pharmaceuticals, Inc) to warn of their contraindication in patients with moderate to severe renal scathe (creatinine room [CrCl], <50-mL/minute) because of the increased risk for toxic reactions.
(more…)
This is a part of article FDA Preventative Changes: DDAVP, Norvir, Cipro CME/CE Taken from "Buy Amoxil" Information Blog